Background: Optimization algorithms provide robust analytical frameworks for assessing hepatocellular carcinoma (HCC) pharmacokinetics based on dynamic positron emission tomography/computed tomography (PET/CT) scans. The aim of this study was to assess the role of estimating HCC pharmacokinetics from PET/ CT scans via the Bayesian optimization (BO) method and the dual-phase (DP) and multiobjective (MO) strategies into BO (DPMO-BO) method. Methods: Five-minute dynamic and one-minute static PET/CT imaging data derived from 27 HCC tumors were used to estimate kinetic parameters (K-1, k(2), k(3), k(4), f(a), v(b), K-i ) via a double-input three-compartment model. The role of pharmacokinetic parameters in distinguishing HCC was compared among the Bayesian method (BM), BO method, and DPMO-BO method. The fitting deviation between the predictions of the model and the actual observations was assessed via the root mean square error (RMSE). Results: The results demonstrated that the BM significantly distinguished HCC from background liver tissues with K-2 , k(3), f(a) , and b(v) (all P<0.05), whereas the BO method achieved this degree of differentiation for af and bv(both P<0.001). The DPMO-BO method resulted in significant differences in all of these parameters (K-1, k(2), k(3), k(4), f(a), v(b), K-i)(all P<0.05). DPMO-BO yielded greater area under the receiver operating characteristic (ROC) curve (AUC) values for K-i (AUC =0.709) than did BO (AUC =0.595, P<0.001). Additionally, reduced RMSEs for HCC and normal liver tissues were observed with DPMO-BO (1.226 and 1.051, respectively) relative to those values obtained with the BM (1.324 and 1.118, respectively) and BO (1.308 and 1.143, respectively). Conclusions: The BO method can be used to assess HCC pharmacokinetics, whereas the DPMO-BO method further enhances diagnostic performance by achieving improved fitting accuracy.